AstraZeneca's Imfinzi with pre-surgery drug boosts survival in bladder cancer trial

AstraZeneca said on Thursday that a late-stage trial of Imfinzi, combined with ​a targeted therapy prior to a ‌surgery, showed significantly improved survival rate in patients with muscle-invasive bladder cancer.